Results 141 to 150 of about 949 (170)
Some of the next articles are maybe not open access.
Varespladib: An Oral Treatment for Snakebite Envenoming
Journal of Current Toxicology and VenomicsJessica Huston, E. Egelund
semanticscholar +2 more sources
Biochimie, 2022 Varespladib (LY315920) is a potent inhibitor of human group IIA phospholipase A2 (PLA2) originally developed to control inflammatory cascades of diseases associated with high or dysregulated levels of endogenous PLA2. Recently, varespladib was also found to inhibit snake venom PLA2 and PLA2-like toxins.
Guilherme H. M. Salvador +8 more
semanticscholar +5 more sources
Biochimica et Biophysica Acta (BBA) - General Subjects, 2021 The treatment for snakebites is early administration of antivenom, which can be highly effective in inhibiting the systemic effects of snake venoms, but is less effective in the treatment of extra-circulatory and local effects. To complement standard-of-care treatments such as antibody-based antivenoms, natural and synthetic small molecules have been ...
Guilherme H. M. Salvador +4 more
semanticscholar +6 more sources
Phospholipase A2 inhibitor varespladib prevents wasp sting-induced nephrotoxicity in rats.
Toxicon, 2022This study aimed to clarify whether varespladib, a phospholipase A2 (PLA2) inhibitor, can be used as a therapeutic agent for wasp sting-induced acute kidney injury (AKI). Rats were divided into control, AKI, and AKI + varespladib groups. The AKI model was established by subcutaneously injecting wasp venom at five different sites in rats.
Rui Wang +5 more
semanticscholar +3 more sources
4 Oral Varespladib for Snakebite Envenoming: The BRAVO International Randomized Controlled Trial
Annals of Emergency Medicine, 2023 C. Gerardo +9 more
semanticscholar +2 more sources
Cardiovascular Toxicology, 2023
In this work, we examined the action of two South American coralsnake (Micrurus corallinus and Micrurus dumerilii carinicauda) venoms on rat heart function in the absence and presence of treatment with Brazilian coralsnake antivenom (CAV) and varespladib (VPL), a potent phospholipase A2 inhibitor. Anesthetized male Wistar rats were injected with saline
Matheus Z. Gaspar +11 more
semanticscholar +3 more sources
In this work, we examined the action of two South American coralsnake (Micrurus corallinus and Micrurus dumerilii carinicauda) venoms on rat heart function in the absence and presence of treatment with Brazilian coralsnake antivenom (CAV) and varespladib (VPL), a potent phospholipase A2 inhibitor. Anesthetized male Wistar rats were injected with saline
Matheus Z. Gaspar +11 more
semanticscholar +3 more sources
American Journal Cardiovascular Drugs, 2011 Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes.
NULL AUTHOR_ID
openalex +3 more sources
Varespladib methyl in cardiovascular disease
Expert Opinion on Investigational Drugs, 2010The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving evidence-based therapies has prompted investigations into complimentary treatments that may reduce residual risk. Analyses of clinical trials in statin-treated patients demonstrate that elevated lipid levels and an activated systemic inflammatory ...
Robert S Rosenson
exaly +4 more sources
Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture
Current Pharmaceutical Biotechnology, 2013 Acute lung injury is a life-threatening condition characterized by surfactant dysfunction and raised secretory phospholipase A2 (sPLA2) activity. Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity ...
Danièle De Luca +9 more
openalex +5 more sources